Internal m 6A and m 7G RNA modifications in hematopoietic system and acute myeloid leukemia
10.1097/CM9.0000000000003073
- VernacularTitle:Internal m 6A and m 7G RNA modifications in hematopoietic system and acute myeloid leukemia
- Author:
Xiaoxu ZHANG
1
;
Yanni MA
;
Jia YU
;
Rui SU
;
Xiaoshuang WANG
Author Information
1. State Key Laboratory of Common Mechanism Research for Major Diseases, State Key Laboratory for Complex, Severe, and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences / Peking Union Medical College, Beijing 100005, China
- Keywords:
N6-methyladenosine;
N7-methylguanine;
Hematopoiesis;
Acute myeloid leukemia;
Therapeutic target;
RNA modifications
- From:
Chinese Medical Journal
2024;137(9):1033-1043
- CountryChina
- Language:Chinese
-
Abstract:
Epitranscriptomics focuses on the RNA-modification-mediated post-transcriptional regulation of gene expression. The past decade has witnessed tremendous progress in our understanding of the landscapes and biological functions of RNA modifications, as prompted by the emergence of potent analytical approaches. The hematopoietic system provides a lifelong supply of blood cells, and gene expression is tightly controlled during the differentiation of hematopoietic stem cells (HSCs). The dysregulation of gene expression during hematopoiesis may lead to severe disorders, including acute myeloid leukemia (AML). Emerging evidence supports the involvement of the mRNA modification system in normal hematopoiesis and AML pathogenesis, which has led to the development of small-molecule inhibitors that target N6-methyladenosine (m 6A) modification machinery as treatments. Here, we summarize the latest findings and our most up-to-date information on the roles of m 6A and N7-methylguanine in both physiological and pathological conditions in the hematopoietic system. Furthermore, we will discuss the therapeutic potential and limitations of cancer treatments targeting m 6A.
